MANIFEST-2: Pelabresib plus Ruxolitinib in JAK Inhibitor–Naïve Myelofibrosis
January 17th 2024Uma Borate, MBBS, and the Oncology Brothers provide insights gleaned from the MANIFEST-2 study, a phase 3, randomized, double-blind study on pelabresib plus ruxolitinib for JAK inhibitor treatment–naïve patients with myelofibrosis.
Watch
TRANSFORM-1: Navitoclax and Ruxolitinib in Untreated Myelofibrosis
January 17th 2024Following ASH 2023, Uma Borate, MBBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the TRANSFORM-1 trial investigating navitoclax plus ruxolitinib in patients with untreated myelofibrosis.
Watch
Identifying Gaps Between HCPs and Patients in HER2-Positive Breast Cancer Treatment
January 17th 2024In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed data from a quality improvement initiative identifying issues for health care professionals and patients with HER2-positive breast cancer.
Watch
HER2CLIMB-02: Tucatinib and T-DM1 for Previously Treated HER2+ Metastatic Breast Cancer
January 11th 2024Daniel Stover, MD, and the Oncology Brothers review results from HER2CLIMB-02, a randomized, double-blind phase 3 trial of tucatinib and T-DM1 in patients with previously treated HER2+ metastatic breast cancer.
Watch
Update from KATHERINE on Adjuvant T-DM1 for Residual Invasive HER2+ Early Breast Cancer
January 11th 2024Medical oncologists discuss the recent update from the KATHERINE trial investigating adjuvant T-DM1 (trastuzumab emtansine) following neoadjuvant chemotherapy in patients with residual invasive HER2+ early breast cancer.
Watch
Sub-Analysis from APHINITY on Adjuvant Pertuzumab and Trastuzumab in HER2+ Breast Cancer
January 11th 2024Following SABCS 2023, Daniel Stover, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the benefit of adjuvant pertuzumab and trastuzumab according to ER and HER2 expression in patients with HER2+ breast cancer.
Watch
Importance of Early Detection and Unmet Needs in MDS
January 10th 2024Clinicians discuss the importance of early detection in patients with MDS as well as providing insights into some of the unmet needs in MDS, such as a better understanding of the role of molecular alterations and its specific impact in MDS.
Watch